Description: Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Home Page: www.evotec.com
Essener Bogen 7
Hamburg,
22419
Germany
Phone:
49 40 560 81 0
Officers
| Name | Title |
|---|---|
| Ms. Laetitia Rouxel | CFO & Member of Management Board |
| Dr. Cord Dohrmann Ph.D. | Chief Scientific Officer & Member of Management Board |
| Dr. Craig Johnstone Ph.D. | COO & Member of Management Board |
| Dr. Christian Wojczewski | Chief Executive Officer |
| Ms. Aurelie Dalbiez | Chief People Officer & Member of Management Board |
| Mr. Volker Braun | Executive VP and Head of Global Investor Relations & ESG |
| Dr. Christian Dargel | EVP Global Head of Legal & Compliance |
| Gabriele Hansen | Senior VP & Head of Global Corporate Communications & Marketing |
| Dr. Ian M. Hunneyball | Senior Vice President of Programme Management & Clinical Operations |
| Dr. David Hallet | Executive Vice President |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 61.3497 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.6069 |
| Price-to-Sales TTM: | 2.0405 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5007 |